Abstract
Lectins are a group of specific proteins that preferentially bind to carbohydrates inside and outside cells. To date, an increasing number of animal lectins have been found and categorized into several families in terms of the significant primary structural homology, while the classification is not always straightforward. These lectins can exert immense biological functions mainly through their specific carbohydrate-protein interactions in a variety of situations. In cancer biology, aberrant glycosylation changes on many glycoproteins and glycolipids are often observed and numerous experimental evidences have revealed that these structural changes are related to tumor malignancy. Galectins, which are broadly expressed animal lectins, can play crucial biological roles in tumor cell-cell or cell-matrix interactions through their binding activities to the tumor cell surface carbohydrate determinants. Certain galectin family proteins have also shown to affect tumor cell survival, signal transduction, and proliferation mainly inside the cell. Selectins, which are one of the C-type lectins and expressed leukocytes and/or vascular endothelium, can also play an immense role in tumor cell adhesion and invasion. In addition, certain annexin family proteins, which are originally known as phospholipid binding proteins, have been revealed to possess the carbohydrate binding activity, and these novel functions in tumors are being unveiled. Understanding how carbohydrate-protein interactions function in tumor cells will be one of the important goals in cancer research. This review focuses on the role of these lectins and their ligands in cancer progression and metastasis.
Keywords: Carbohydrate-binding proteins, lectin, galectin, selectin, annexin
Anti-Cancer Agents in Medicinal Chemistry
Title: Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Volume: 8 Issue: 1
Author(s): Avraham Raz and Susumu Nakahara
Affiliation:
Keywords: Carbohydrate-binding proteins, lectin, galectin, selectin, annexin
Abstract: Lectins are a group of specific proteins that preferentially bind to carbohydrates inside and outside cells. To date, an increasing number of animal lectins have been found and categorized into several families in terms of the significant primary structural homology, while the classification is not always straightforward. These lectins can exert immense biological functions mainly through their specific carbohydrate-protein interactions in a variety of situations. In cancer biology, aberrant glycosylation changes on many glycoproteins and glycolipids are often observed and numerous experimental evidences have revealed that these structural changes are related to tumor malignancy. Galectins, which are broadly expressed animal lectins, can play crucial biological roles in tumor cell-cell or cell-matrix interactions through their binding activities to the tumor cell surface carbohydrate determinants. Certain galectin family proteins have also shown to affect tumor cell survival, signal transduction, and proliferation mainly inside the cell. Selectins, which are one of the C-type lectins and expressed leukocytes and/or vascular endothelium, can also play an immense role in tumor cell adhesion and invasion. In addition, certain annexin family proteins, which are originally known as phospholipid binding proteins, have been revealed to possess the carbohydrate binding activity, and these novel functions in tumors are being unveiled. Understanding how carbohydrate-protein interactions function in tumor cells will be one of the important goals in cancer research. This review focuses on the role of these lectins and their ligands in cancer progression and metastasis.
Export Options
About this article
Cite this article as:
Raz Avraham and Nakahara Susumu, Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152008783330833
DOI https://dx.doi.org/10.2174/187152008783330833 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA An Overview of Nano Delivery Systems for Targeting RNA Interference-based Therapy in Ulcerative Colitis
Current Pharmaceutical Design Erythropoietin and Oxidative Stress
Current Neurovascular Research Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Eating Green: Shining Light on the Use of Dietary Phytochemicals as a Modern Approach in the Prevention and Treatment of Head and Neck Cancers
Current Topics in Medicinal Chemistry Salinomycin Suppresses Tumorigenicity of Liver Cancer Stem Cells and Wnt/Beta-catenin Signaling
Current Stem Cell Research & Therapy Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Phenolic Compounds: the Role of Redox Regulation in Neurodegenerative Disease and Cancer
Mini-Reviews in Medicinal Chemistry Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets